US Pharmacopeia

If the four statements below describe you or someone you know, this is your sign to learn about the opportunity to serve as a #USPExpertVolunteer. ✔ I’m a pharmaceutical sciences expert working in academia, industry, or healthcare. ✔ I’m passionate about global #PublicHealth and pharmaceutical product quality. ✔ I’m open to scientific debate in a collaborative environment. ✔ I’m interested in advancing access to quality medicines, foods, and supplements for all. Visit Bit.ly/USPExpertVolunteer for more and tag your colleagues + collaborators who should consider applying to be a US Pharmacopeia Expert Volunteer in a comment. ⤵

Heading to SupplySide West, October 30 and 31? Stop by and see us at Booth 3883 to learn about USP’s standards and solutions that help ensure dietary supplement and food ingredient quality. Ask us how you can participate in our standards development process! #SSWExpo

#DYK? We’re on a mission to recruit the largest, most diverse, and qualified #USPExpertVolunteer cohort (ever) to serve in our upcoming 2025-2030 cycle! At US Pharmacopeia, the unique perspectives and cross-disciplinary knowledge of our Expert Volunteers lead to better quality solutions and a greater impact on global #PublicHealth. That’s why we’re taking conference season by storm to spread the word about how pharmaceutical sciences experts can amplify their impact in a big way. Check out snapshots of USP staff and current volunteers in action and visit Bit.ly/USPExpertVolunteer to learn more about the opportunity to join our global network. Have you connected with USP at your latest pharma sci industry event? Drop a comment ⤵ to let us know or share where you’ll be next (and we might just see you there).

The USAID-funded PQM+ program developed a summary of its landscape study on medicines used to treat and prevent neglected tropical diseases (#NTDs). The study assessed the supply chain of seven key medicines, with an aim to increase local capacity for manufacturing and procuring NTD treatments in sub-Saharan #Africa and #Asia. Learn about the key findings and recommendations of the study here ➡ : https://ow.ly/4o9q50TRRYr #HealthSystems

#ICYMI: To support increased access to quality medicines and vaccines in Africa, we launched #USPAccess4Africa, in collaboration with Africa CDC, African Union Development Agency-NEPAD, the Association of African Universities, and the Federation of African Pharmaceutical Manufacturers Associations (FAPMA). The initiative aims to strengthen the region’s pharmaceutical sector by equipping African-based regulators with free access to USP-NF and USP Education resources designed to support the region’s production of quality medical products. Learn more and register: Bit.ly/USPAccess4Africa. #WednesdayWisdom #RegulatoryAffairs

Meet Otilia Koo, senior pharma executive, leading expert on excipients, #USPExpertVolunteer, and current Committee Chair helping lead US Pharmacopeia efforts on quality standards and solutions for complex excipients. Whether it’s combatting substandard and falsified medicines or strengthening the pharmaceutical supply chain – choosing to volunteer with USP like Otilia means being a driving force for a healthier, safer world. Learn more: Bit.ly/USPExpertVolunteer. Want to hear more about Otilia’s experience including the invaluable benefits she’s gained as a result? If you’re at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms’ #PharmSci360, you can join Otilia in-person during our Women in PharmSci Breakfast tomorrow on Wednesday, Oct. 22 at 7:30 a.m. MT. Visit: https://cdmcd.co/QGdaBk for event details. #Excipients #PublicHealth

The public comment period for the  draft of USP Drug Classification 2025 (USP DC 2025) is open until October 31, 2024. The anticipated publication date for USP DC 2025 is January 15, 2025. We invite you to review the proposed draft➡️: https://ow.ly/ySUh50TQb4M #Pharmaceuticals #DrugClassification #USPScience

We have exciting news! USP has acquired Stratix Labs – a microbiology technology company that leverages its innovative preservation technology – to develop microbiological quality control testing products. This is a significant milestone for USP and the industry, as the addition of Stratix Labs’ technology and products significantly expands our portfolio of microbiological solutions and will help address the long-standing industry gap in microbial contamination control and biosafety. Microbiological testing is a universal requirement to ensure fundamental microbial contamination control measures are in place during the development of numerous manufactured and compounded products across pharmaceuticals, foods, and more. The innovative technology from Stratix Labs, combined with USP’s expertise in quality control, will greatly enhance the industry’s ability to detect contamination at every stage of a product’s development and lifecycle. Learn more about the acquisition and our new product offerings➡️: https://ow.ly/Rkke50TPH8z

The persistent challenges of drug shortages and nitrosamine impurities in pharmaceuticals were the topics of discussion in two recent interviews, published by The Medicine Maker, with USP experts Vimala Raghavendran Vice President, Informatics Product Development and Naiffer Romero, Principal Scientist and community manager of USP’s Nitrosamines Exchange Vimala discussed the need for significant shifts in the current market to develop more sustainable and resilient medicines supply chains, while noting that certain medicines are at a higher risk of shortage due to certain vulnerability factors. While discussing nitrosamine impurities and their impact on medicine quality, Naiffer highlighted the evolving challenges faced by both the pharmaceutical industry and regulatory agencies in addressing these impurities as well as USP’s commitment to providing trustworthy reference materials. Read more⤵️ Vimala's interview: https://ow.ly/BvCW50TPMfH Naiffer's interview: https://ow.ly/OzXS50TPMfG

We are excited to announce the successful conclusion of the Fourth MENA Regional Chapter Meeting of the USP Convention, held on Tuesday, October 15, 2024. This hybrid event, hosted by the Jordanian Association of Pharmaceutical Manufacturers (JAPM) in Amman, Jordan, brought together 32 representatives from regulatory bodies and pharmaceutical associations across the Middle East and North Africa. The meeting began with a warm welcome from Alessandro Slama, USP’s Vice President of Regional Program Operations, followed by an insightful update from Hanan Sboul, MENA Chapter Chairperson and General Secretary of JAPM, on the chapter’s activities and upcoming transition. Zakiya Kurdi, USP’s Director of Public Policy and Regulatory Affairs for EMEA, then provided a comprehensive overview of joint initiatives between USP and its convention members since the last chapter meeting. A key part of the event featured presentations by convention members, who shared their organizational priorities and explored how USP can support their efforts. Esteemed speakers represented key bodies, including the Egyptian DA, Jordanian FDA, Abu Dhabi Department of Health, Drug Department of Dubai, Algerian NPP, Morocco DMP, Tunisian LNCM, Saudi Pharma and Bio Cluster, Chamber of Pharmaceutical Industry Egypt, and Arab Union of Pharma Manufacturers AUPAM. The discussions highlighted shared priorities and laid the groundwork for ongoing collaboration to enhance medicine quality across the MENA region. We extend our sincere gratitude to all participants for their valuable contributions and look forward to continuing our collective efforts to advance regulatory and pharmaceutical standards in the region